The EDC3 Knockout A2780 Polyclonal Cells product comprises a heterogenous population of A2780 human ovarian carcinoma cells that have undergone CRISPR/Cas9-mediated disruption of the EDC3 gene, generating a loss-of-function model for studying mRNA decay pathways. As a polyclonal knockout product, this reagent reflects a mixed cell pool with targeted EDC3 gene disruption across the population, suitable for experiments that do not require clonal isolation but benefit from a bulk knockout model.
The A2780 parental cell line is a well-characterized model of human epithelial ovarian carcinoma, originally established from an untreated patient and known for its sensitivity to cisplatin. This cell line is widely employed in chemoresistance research and provides a relevant tumor context for investigating post-transcriptional gene regulation in ovarian cancer.
EDC3 (enhancer of mRNA-decapping protein 3) functions as a scaffold protein that enhances the catalytic activity of the decapping enzyme DCP2, thereby promoting 5??-to-3?? exonucleolytic degradation of mRNAs by XRN1. EDC3 is an integral component of P-bodies, where it interacts with factors such as DCP1A, DDX6, LSM14A, and PATL1 to coordinate mRNA decapping and decay. Upstream, EDC3 activity is regulated by cellular stress stimuli??including oxidative stress and nutrient deprivation??and mTOR signaling. Its targets include AU-rich element (ARE)-containing transcripts like c-FOS, IL-8, and TNF-??, linking EDC3 to inflammatory and stress-responsive gene expression programs.
In the context of A2780 ovarian carcinoma cells, disruption of EDC3 is expected to impair P-body assembly and stabilize a subset of mRNAs that may contribute to oncogenic or stress-adaptive phenotypes. Given the role of mRNA stability in chemotherapy response, this model provides a tool to explore how altered decapping activity influences cisplatin sensitivity and chemoresistance mechanisms. The polyclonal knockout population preserves the genetic heterogeneity of the tumor cell line while allowing assessment of EDC3-dependent phenotypes in a bulk culture setting.
Researchers can employ this product in a variety of experimental applications, including western blotting and immunofluorescence to confirm EDC3 loss and monitor P-body markers, RT-qPCR or RNA-seq to identify transcriptome-wide changes in mRNA stability, actinomycin D chase assays to directly measure decay rates, and functional assays such as cell viability, migration, invasion, and cisplatin sensitivity tests to evaluate phenotypic consequences. This knockout model is particularly suited for studies of post-transcriptional control in ovarian cancer and stress granule biology. For additional information or technical support, please contact Ascent Research.
